CORDIS
EU research results

CORDIS

English EN

Beta Cell Generation by Stem Cell-Derived Implants in Diabetes

Project information

Grant agreement ID: 681070

Status

Ongoing project

  • Start date

    1 December 2015

  • End date

    31 August 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 800 000

  • EU contribution

    € 6 200 000

Coordinated by:

VRIJE UNIVERSITEIT BRUSSEL

Belgium

Objective

Despite improved treatment, diabetes remains a chronic disease with major health risks and heavy burden on patients and society. Serious forms are caused by depletion in pancreatic beta cells and associated loss in insulin’s homeostatic control throughout life. Their cure requires restoration of a metabolically adequate beta cell mass. Implants of beta cell grafts prepared from human pancreases have shown proof-of-principle but also the need for developing a large-scale source for therapeutic cells. Our objective is to generate a functional beta cell mass by stem cell-derived implants in diabetes patients. A combined preclinical and clinical project will search recipient and implant conditions for formation and maturation of beta cells in subcutaneous implants of device-encapsulated pancreatic endodermal cells that are derived from human embryonic stem cells (hu-ES) and manufactured for clinical studies. We collected preclinical evidence for the therapeutic potential of this implant from comparison with clinically used human beta cell grafts. State-of-the art methods and markers have been developed to investigate the biology of implants and to monitor host immune and innate reactivity. This approach helps understand the basis for metabolic outcome and identify targets for improvement. Pilot studies examine the influence of the (auto)immune status of the patients. Data will determine transition to clinical efficacy studies, or indicate the need for further laboratory development. Implants in preclinical models will guide modifications in clinical protocols, and explore the biologic properties of grafts derived from human induced pluripotent stem cell (iPSc) as can also be prepared from diabetes patients. Our consortium joins innovating cells, methods, markers and minds in a unique combination of expert clinical, academic and industry activities that need each other to make progress in an ambitious program.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

VRIJE UNIVERSITEIT BRUSSEL

Address

Pleinlaan 2
1050 Brussel

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 100 000

Participants (7)

VIACYTE, INC CORPORATION

United States

EU Contribution

€ 600 000

OSPEDALE SAN RAFFAELE SRL

Italy

EU Contribution

€ 1 200 000

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 600 000

NESTEC SA

Switzerland

NESTEC SA

Switzerland

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE

France

EU Contribution

€ 100 000

CENTER FOR BETA CELL THERAPY IN DIABETES

Belgium

EU Contribution

€ 600 000

Project information

Grant agreement ID: 681070

Status

Ongoing project

  • Start date

    1 December 2015

  • End date

    31 August 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 800 000

  • EU contribution

    € 6 200 000

Coordinated by:

VRIJE UNIVERSITEIT BRUSSEL

Belgium